The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation.

The protein tyrosine phosphatase (PTP) PTPL1/PTPN13 is a candidate tumor suppressor gene. Indeed, PTPL1 activity has been reported recently to be decreased through somatic mutations, allelic loss, or promoter methylation in some tumors. We showed previously that its expression was necessary for inhibition of Akt activation and induction of apoptosis by antiestrogens in breast cancer cells. Implications of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway in cancer progression are now well established, and our study was therefore designed to define whether PTPL1 is sufficient to inhibit this pathway and, if so, to identify a direct substrate of this PTP, which may trigger a proapoptotic effect. We first show by complementary approaches that PTPL1 specifically dephosphorylates insulin receptor substrate-1 (IRS-1) in vitro and in cellulo. Next, our experiments using a dominant-negative mutant and RNA interference confirm the crucial role of PTPL1 in IRS-1 dephosphorylation. Finally, we report that PTPL1 expression is sufficient to block the IRS-1/PI3K/Akt signaling pathway, to inhibit the insulin-like growth factor-I effect on cell survival, and to induce apoptosis. Altogether, these data provide the first evidence for a direct positive role of the putative tumor suppressor gene PTPL1/PTPN13 on apoptosis and identify its target in the IRS-1/PI3K/Akt signaling pathway.

[1]  R. Kobayashi,et al.  Identification of the Cell Cycle Regulator VCP (p97/CDC48) as a Substrate of the Band 4.1-related Protein-tyrosine Phosphatase PTPH1* , 1999, The Journal of Biological Chemistry.

[2]  Ding‐Shinn Chen,et al.  Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  E. Cuppen,et al.  A FERM domain governs apical confinement of PTP-BL in epithelial cells. , 1999, Journal of cell science.

[4]  B. Neel,et al.  Combinatorial control of the specificity of protein tyrosine phosphatases. , 2001, Current opinion in cell biology.

[5]  E. Cuppen,et al.  No Evidence for Involvement of Mouse Protein-tyrosine Phosphatase-BAS-like Fas-associated Phosphatase-1 in Fas-mediated Apoptosis* , 1997, The Journal of Biological Chemistry.

[6]  T. Whiteside,et al.  FAP‐1‐mediated activation of NF‐κB induces resistance of head and neck cancer to fas‐induced apoptosis , 2007, Journal of cellular biochemistry.

[7]  A. Alonso,et al.  Subcellular localization of intracellular protein tyrosine phosphatases in T cells , 2000, European journal of immunology.

[8]  John Calvin Reed,et al.  FAP-1: a protein tyrosine phosphatase that associates with Fas. , 1995, Science.

[9]  M. Nakahira,et al.  Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. , 2007, Immunity.

[10]  T. Hunter,et al.  Signaling—2000 and Beyond , 2000, Cell.

[11]  D. Leroith,et al.  Insulin Receptor Substrate-1 Pleckstrin Homology and Phosphotyrosine-binding Domains Are Both Involved in Plasma Membrane Targeting* , 2001, The Journal of Biological Chemistry.

[12]  T. Sugiyama,et al.  Fas‐associated phosphatase‐1 promotes Fas‐mediated apoptosis in human colon cancer cells: Novel function of FAP‐1 , 2006, Journal of gastroenterology and hepatology.

[13]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[14]  J. Inazawa,et al.  PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3. , 1996, Genomics.

[15]  Maria Deak,et al.  Crystal Structure of the PTPL1/FAP-1 Human Tyrosine Phosphatase Mutated in Colorectal Cancer , 2004, Journal of Biological Chemistry.

[16]  G. Freiss,et al.  Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells. , 1998, Molecular endocrinology.

[17]  Q. Tao,et al.  Epigenetic disruption of two proapoptotic genes MAPK10/JNK3 and PTPN13/FAP-1 in multiple lymphomas and carcinomas through hypermethylation of a common bidirectional promoter , 2006, Leukemia.

[18]  M. Tremblay,et al.  Substrate-trapping techniques in the identification of cellular PTP targets. , 2005, Methods.

[19]  D. Leroith,et al.  The Insulin-like Growth Factor-I Receptor Is Required for EWS/FLI-1 Transformation of Fibroblasts* , 1997, The Journal of Biological Chemistry.

[20]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.

[21]  G. Raisman,et al.  Improved post-embedding immunocytochemistry of myelinated nervous tissue for electron microscopy , 2000, Journal of Neuroscience Methods.

[22]  G. Lienhard,et al.  A Novel 160-kDa Phosphotyrosine Protein in Insulin-treated Embryonic Kidney Cells Is a New Member of the Insulin Receptor Substrate Family* , 1997, The Journal of Biological Chemistry.

[23]  P. Gruss,et al.  Distribution of a murine protein tyrosine phosphatase BL‐β‐galactosidase fusion protein suggests a role in neurite outgrowth , 1998, Developmental dynamics : an official publication of the American Association of Anatomists.

[24]  T. Onytiganis.  Development of ''substrate-trapping'' mutants to identify physiological substrates of protein tyrosine phosphatases , 1997 .

[25]  G. Freiss,et al.  Protein tyrosine phosphatases and breast cancer. , 2004, Critical reviews in oncology/hematology.

[26]  G. Freiss,et al.  Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. , 1994, Molecular endocrinology.

[27]  C. Hellberg,et al.  Protein-tyrosine phosphatases and cancer , 2006, Nature Reviews Cancer.

[28]  F. Oerlemans,et al.  Mild impairment of motor nerve repair in mice lacking PTP-BL tyrosine phosphatase activity. , 2004, Physiological genomics.

[29]  K. Belguise,et al.  Receptor-interacting protein 140 binds c-Jun and inhibits estradiol-induced activator protein-1 activity by reversing glucocorticoid receptor-interacting protein 1 effect. , 2003, Molecular Endocrinology.

[30]  A. Prescott,et al.  Interaction of the protein tyrosine phosphatase PTPL1 with the PtdIns(3,4)P2-binding adaptor protein TAPP1. , 2003, The Biochemical journal.

[31]  K. S. Erdmann.  The protein tyrosine phosphatase PTP-Basophil/Basophil-like. Interacting proteins and molecular functions. , 2003, European journal of biochemistry.

[32]  Toshiyuki Fukada,et al.  A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  M. Zimmer,et al.  EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. , 2002, Molecular cell.

[34]  A. Üren,et al.  PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis , 2005, Oncogene.

[35]  N. Tonks,et al.  Protein tyrosine phosphatases: from genes, to function, to disease , 2006, Nature Reviews Molecular Cell Biology.

[36]  G. Freiss,et al.  Membrane targeting of protein tyrosine phosphatase PTPL1 through its FERM domain via binding to phosphatidylinositol 4,5-biphosphate , 2003, Journal of Cell Science.

[37]  C. Prébois,et al.  Protein-tyrosine Phosphatase PTPL1/FAP-1 Triggers Apoptosis in Human Breast Cancer Cells* , 2002, The Journal of Biological Chemistry.